COVID-19 Booster for Children Ages 5-11 in Laredo

Translate to Spanish or other 102 languages!

 The U.S. Food and Drug Administration authorized a single booster of the Pfizer-BioNTech COVID-19 vaccine for individuals 5 through 11 years of age at least five months after completion of their primary series. Image for illustration purposes
The U.S. Food and Drug Administration authorized a single booster of the Pfizer-BioNTech COVID-19 vaccine for individuals 5 through 11 years of age at least five months after completion of their primary series. Image for illustration purposes

Mega Doctor News

- Advertisement -

LAREDO, Texas – The U.S. Food and Drug Administration authorized a single booster of the Pfizer-BioNTech COVID-19 vaccine for individuals 5 through 11 years of age at least five months after completion of their primary series. 

Pfizer’s clinical trial showed that a booster dose of the Pfizer-BioNTech COVID-19 Vaccine prompted a robust immune response in this age group, generating neutralizing antibodies against the SARS-CoV-2 virus regardless of prior SARS-CoV-2 infection. The actions taken by the FDA would make all Americans 5 and older eligible for a booster shot.

“FDA/CDC pediatric booster approval ensures a higher level of COVID-19 protection amongst children over the summer and when returning to school in the fall,” says Dr. Richard Chamberlain, Health Director, “We continue to urge our community to get vaccinated; vaccines work, vaccines are safe, and vaccines save lives. Stay up-to-date with your vaccines”.

- Advertisement -

The City of Laredo Health Department will provide COVID-19 boosters shots to children 5-11 years of age starting Friday, May 20, 2022. Vaccines will be available at the City of Laredo Health Department Clinic located at 2600 Cedar Ave. or across the city of Laredo via our Mobile Health Clinic

For more information or updates, please follow our social media channels at @LaredoHealth or call (956) 236-8311.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health Recognizes November as “National Hospice and Palliative Care” Month

DHR Health is pleased to recognize November as “National Hospice and Palliative Care Month.”  As we highlight National Hospice and Palliative Care Month, let us remember that healthcare is not solely about treating diseases but also about care for people at end of life.

STHS Heart Earns Healthgrades Five-Star Rating for Pacemaker Procedures

Healthgrades, the leading online resource for information about physicians and hospitals, has named STHS Heart a Five-Star Recipient for Pacemaker Procedures in 2027 for the second consecutive year, recognizing the facility's superior clinical outcomes and commitment to patient care.

AMA Advises Patients to Check with Doctors on Web Advice

The internet offers no shortage of health advice. But with misleading medical claims spread across social media, search engines, and AI platforms, finding trustworthy answers can be a challenge. 

FDA Authorizes Focused Ultrasound Treatment for Varicose Veins

Theraclion has announced that the US Food and Drug Administration (FDA) has granted De Novo authorization for its Sonovein device to treat superficial venous reflux in great saphenous veins (GSV), the main cause of varicose veins. This is the first noninvasive focused ultrasound platform to treat varicose veins, which affect approximately one third of adults.
- Advertisement -